Implant Sciences Sells 12 QS-B220 Explosives Trace Detectors to South Korea's Largest Airport
Units to replace previously installed competing products at Incheon International Airport
September 09, 2014 --
WILMINGTON, Mass., Sept. 9, 2014 /PRNewswire/ --Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today it has sold 12 QS-B220 desktop explosives and drugs trace detectors to Incheon International Airport Corporation, operator of Incheon International Airport, the largest airport in South Korea. Implant Sciences' ETDs will be deployed for airport security and will replace existing systems the airport had in place from a competitor.
"This customer was looking to replace a competing installed product with a more cost-efficient, high-performance ETD from a company that provides superior customer service and support," stated Dr. Darryl Jones, Implant Sciences' Vice President of Global Sales and Marketing. "This airport had been evaluating our QS-B220, but the sale was contingent upon our system being added to the TSA's Qualified Products List. Upon being placed on the TSA's QPL, the customer immediately placed their order."
"At Implant Sciences, our commitment to a culture of service is a priority and we believe it differentiates us in the market. Our local distributor, A&T, has a strong track record, is one of the most active leaders of the security market in South Korea, and will provide service and support to Incheon International Airport. We are pleased to work with them," Jones added.
About the QS-B220 Desktop Explosives and Drugs Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide. Implant Sciences is only the third manufacturer, and the sole American-owned company, to currently have an ETD system named as a Qualified Product by the U.S. Transportation Security Administration. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation
Copyright 2014 PR Newswire. All Rights Reserved